Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18581735 | COSMETIC SKINCARE COMPOSITION COMPRISING PROBIOTIC MICROORGANISMS AND PREBIOTIC COMPOUNDS | February 2024 | November 2025 | Abandon | 21 | 1 | 0 | No | No |
| 17957186 | STABLE AGROCHEMICAL COMPOSITION | September 2022 | January 2026 | Allow | 40 | 4 | 1 | Yes | No |
| 17892257 | COMPOSITION FOR TREATING AND/OR PREVENTING A HANGOVER | August 2022 | June 2025 | Abandon | 34 | 3 | 1 | No | No |
| 17775287 | PERIPHERALLY ACTING CANNABIDIOL (CBD)-CONTAINING COMPOUNDS AND USES THEREOF FOR ENHANCING FEMALE SEXUAL FUNCTION OR TREATING FEMALE SEXUAL DISORDERS | July 2022 | August 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17688126 | METHOD OF TREATING A SKIN CONDITION | March 2022 | February 2026 | Abandon | 47 | 5 | 0 | No | No |
| 17683813 | SYSTEMS AND METHODS FOR DELIVERY OF ACTIVES & HEALING TISSUE | March 2022 | September 2025 | Allow | 43 | 4 | 1 | Yes | No |
| 17623147 | SUSTAINED-RELEASE LIPID COMPOSITION AND PREPARATION METHOD THEREFOR | December 2021 | November 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17548592 | AQUEOUS LIQUID COSMETIC AND PEN TYPE COSMETIC PRODUCT | December 2021 | March 2025 | Abandon | 39 | 3 | 0 | Yes | No |
| 17617738 | LIPOSOME FORMULATION | December 2021 | February 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17616610 | POLYMERIC MICELLE COMPLEXES, FORMULATIONS, AND USES THEREOF | December 2021 | March 2026 | Abandon | 51 | 1 | 1 | No | No |
| 17523532 | Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto | November 2021 | October 2024 | Abandon | 35 | 2 | 0 | No | No |
| 17510843 | PEST CONTROL INCLUDING COMBINED MATING DISRUPTION AND TRAPPING | October 2021 | May 2025 | Abandon | 42 | 4 | 1 | Yes | No |
| 17601358 | TRANSDERMAL MEDICAMENT | October 2021 | February 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17437994 | NEW COSMETIC USE OF POROUS SPHERES OF METAL OXIDE | September 2021 | November 2024 | Abandon | 39 | 2 | 1 | Yes | No |
| 17437864 | NASAL DRESSINGS AND STENTS | September 2021 | March 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17435552 | NON-STEROIDAL ANTI-INFLAMMATORY LYOPHILIZED PHARMACEUTICAL COMPOSITION | September 2021 | March 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17294566 | SUNSCREEN COMPOSITION COMPRISING SURFACE-DEFECTED CERIUM OXIDE PARTICLES, AND PREPARATION METHOD THEREFOR | May 2021 | March 2026 | Abandon | 58 | 3 | 1 | Yes | No |
| 17290666 | HAIR COSMETIC AND HAIR TREATMENT METHOD USING SAME | April 2021 | September 2025 | Abandon | 53 | 4 | 1 | Yes | No |
| 17290618 | GRAFT COPOLYMERS, METHODS OF FORMING GRAFT COPOLYMERS, AND METHODS OF USE THEREOF | April 2021 | August 2025 | Allow | 52 | 1 | 1 | No | No |
| 17244607 | HAIR TREATMENT PRODUCT AND METHOD OF MANUFACTURE AND USE | April 2021 | February 2025 | Abandon | 45 | 3 | 1 | No | No |
| 17239809 | ENCAPSULATED LIQUID COMPOSITION | April 2021 | April 2025 | Abandon | 48 | 2 | 0 | Yes | No |
| 17282996 | COMPOSITIONS FOR ADMINISTRATION TO ANIMALS TO INCREASE GUT NON-PROTEIN NITROGEN LEVELS | April 2021 | October 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17282157 | IONIZABLE AMINE LIPIDS | April 2021 | December 2025 | Abandon | 57 | 2 | 1 | Yes | No |
| 17282276 | STOMA POWDER INCLUDING SKIN HEALTH INGREDIENTS | April 2021 | September 2025 | Abandon | 53 | 2 | 0 | No | Yes |
| 17278492 | SOLID WATER-IN-OIL EMULSION COSMETIC | March 2021 | October 2024 | Abandon | 43 | 4 | 0 | Yes | No |
| 17278039 | MICROEMULSION FORMULATION CONTAINING CLACYFOS HERBICIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | March 2021 | March 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17275819 | WATER-IN-OIL COMPOSITION FOR EXTERNAL APPLICATION TO SKIN | March 2021 | February 2025 | Abandon | 48 | 5 | 0 | No | No |
| 17271727 | SULFORAPHANE-MELATONIN-LIKE COMPOUND | February 2021 | October 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17272062 | A CURCUMIN LOADED STABILIZED POLYMERIC NANOPARTICLES WITH INCREASED SOLUBILITY AND PHOTO-STABILITY AND A GREEN PROCESS FOR THE SYNTHESIS THEREOF | February 2021 | July 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17272205 | USE OF AMINO ACID BASED NUTRIENTS AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | February 2021 | May 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17261663 | NOVEL CARRIER FLUIDS FOR LIQUID FUNGAL SPORE FORMULATIONS | January 2021 | January 2026 | Abandon | 60 | 3 | 1 | Yes | No |
| 15733291 | CO-SYNTHESIS OF PHYLLOMINERALS WITH METALLIC PARTICLES AND PRODUCTS OBTAINED THERE-FROM | June 2020 | July 2024 | Abandon | 49 | 4 | 1 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KETCHAM, KAREN A.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KETCHAM, KAREN A works in Art Unit 1614 and has examined 26 patent applications in our dataset. With an allowance rate of 7.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 48 months.
Examiner KETCHAM, KAREN A's allowance rate of 7.7% places them in the 1% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KETCHAM, KAREN A receive 2.12 office actions before reaching final disposition. This places the examiner in the 57% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by KETCHAM, KAREN A is 48 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +3.8% benefit to allowance rate for applications examined by KETCHAM, KAREN A. This interview benefit is in the 26% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 0.0% of applications are subsequently allowed. This success rate is in the 0% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 0% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 0.0% of appeals filed. This is in the 0% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 200.0% are granted (fully or in part). This grant rate is in the 98% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.